Lenalidomide in patients with cisplatin-refractory and multiply relapsed germ cell tumors.
Standard
Lenalidomide in patients with cisplatin-refractory and multiply relapsed germ cell tumors. / Oechsle, Karin; Bokemeyer, Carsten; Honecker, Friedemann.
In: J CANCER RES CLIN, Vol. 136, No. 1, 1, 2010, p. 165-167.Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review
Harvard
APA
Vancouver
Bibtex
}
RIS
TY - JOUR
T1 - Lenalidomide in patients with cisplatin-refractory and multiply relapsed germ cell tumors.
AU - Oechsle, Karin
AU - Bokemeyer, Carsten
AU - Honecker, Friedemann
PY - 2010
Y1 - 2010
N2 - OBJECTIVE: Treatment options are still limited in patients with cisplatin-refractory and multiply relapsed germ cell tumors. We evaluated the efficacy and tolerability of lenalidomide within a compassionate use concept. PATIENTS AND METHODS: Four patients multiply relapsed after platin-based chemotherapies without any further standard treatment option received 25 mg lenalidomide orally on days 1-21 of a 28-day cycle. RESULTS: All four patients were pretreated with a median number of seven lines of previous chemotherapy (range 4-8), all including platin-based high-dose chemotherapy. After 4 weeks of lenalidomide treatment all patients had progressive disease with increase in serum tumor markers and progression in computed tomography. Median survival time was 8 weeks (range 5-17). The toxicity profile was favorable. No severe toxicities related to lenalidomide occurred in these patients. CONCLUSION: Lenalidomide was well tolerated and showed efficacy in heavily pretreated patients with cisplatin-refractory and multiply relapsed germ cell tumors.
AB - OBJECTIVE: Treatment options are still limited in patients with cisplatin-refractory and multiply relapsed germ cell tumors. We evaluated the efficacy and tolerability of lenalidomide within a compassionate use concept. PATIENTS AND METHODS: Four patients multiply relapsed after platin-based chemotherapies without any further standard treatment option received 25 mg lenalidomide orally on days 1-21 of a 28-day cycle. RESULTS: All four patients were pretreated with a median number of seven lines of previous chemotherapy (range 4-8), all including platin-based high-dose chemotherapy. After 4 weeks of lenalidomide treatment all patients had progressive disease with increase in serum tumor markers and progression in computed tomography. Median survival time was 8 weeks (range 5-17). The toxicity profile was favorable. No severe toxicities related to lenalidomide occurred in these patients. CONCLUSION: Lenalidomide was well tolerated and showed efficacy in heavily pretreated patients with cisplatin-refractory and multiply relapsed germ cell tumors.
M3 - SCORING: Zeitschriftenaufsatz
VL - 136
SP - 165
EP - 167
JO - J CANCER RES CLIN
JF - J CANCER RES CLIN
SN - 0171-5216
IS - 1
M1 - 1
ER -
